...
首页> 外文期刊>Current clinical pharmacology >Management of Hypertension-Journey from Single Drug Therapy to Multitargeted Ligand Therapy: A Clinical Overview.
【24h】

Management of Hypertension-Journey from Single Drug Therapy to Multitargeted Ligand Therapy: A Clinical Overview.

机译:从单一药物治疗到多目标配体治疗的高血压历程管理:临床概述。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Hypertension is recognized as one of the leading risk factors for human morbidity and mortality. It is a major risk factor for myocardial infarction, congestive heart failure, stroke, and endstage renal disease. The difficulty in controlling hypertension is related, at least in part, to the complex pathogenesis of hypertension. In spite of the availability of variety of antihypertensive agents, the control of blood pressure in the general population is at best inadequate. It is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect to side effect profile compared to the use of a selective ligand. Fixed combinations of drugs and multitargeted ligands provide answers to the problem of hypertension. This review provides a status report of current antihypertensive drug therapy with fixed combination of drugs and evolvement of multitargeted ligands for better management of the disease.
机译:高血压被认为是人类发病率和死亡率的主要危险因素之一。它是心肌梗塞,充血性心力衰竭,中风和晚期肾病的主要危险因素。控制高血压的困难至少部分与高血压的复杂发病机制有关。尽管可以使用多种降压药,但一般人群的血压控制至多还是不够的。已经认识到,与使用选择性配体相比,几个靶标的平衡调节可以提供优于副作用的优异治疗效果。药物和多靶点配体的固定组合为高血压问题提供了答案。这篇综述提供了目前的降压药物疗法的现状报告,该疗法具有固定的药物组合和用于更好地控制疾病的多目标配体的演变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号